October 7, 2019
Dr. Rachel Moore Leads Study for Long-Term Safety and Effectiveness of ORBERA™ Gastric Balloon
Moore Metabolics is at the forefront of weight loss innovation, thanks to Dr. Rachel Moore’s proactive pursuit of the most effective weight loss solutions to restore her patients health and confidence. We are proud to share a recent press release from Apollo Endosurgery, the makers of the ORBERA™ Gastric Balloon regarding their U.S. post-approval study, which announces that Dr. Moore, a lead investigator in the study to evaluate the long-term safety and effectiveness of ORBERA™, has enrolled the first patient participant.
The gastric balloon is a non-surgical weight loss device that provides a temporary tool along with a supportive program to kickstart weight loss for patients who are moderately overweight. The study aims to demonstrate the effectiveness and safety of the ORBERA™ gastric balloon. Initial clinical trials showed that gastric balloon patients lost 3.1 times more weight than patients who used diet and exercise alone. Dr. Moore, who was one of the first surgeons in Louisiana to offer the gastric balloon procedure, says that “The resulting data will help clinicians worldwide improve the treatment of obesity with a proven, minimally invasive option.”
Dr. Rachel Moore and the team at Moore Metabolics are committed to providing compassionate and effective care for people struggling with obesity, while also advocating for better treatment.
For more information about the gastric balloon, or other weight loss solutions, contact us today.